equity investment
-
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Congratulations! This is the latest cross-border licensing out deal by a pharma/biotech in China